Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.80 | N/A | +85.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.80 | N/A | +85.57% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management maintained a neutral tone during the earnings call, focusing on long-term growth strategies. They did not provide specific guidance or revenue figures.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company expressed confidence in its long-term strategy despite the lack of detailed financials.
Ligand Pharmaceuticals reported a strong earnings per share figure, significantly beating expectations. However, the stock fell by 8.43% in reaction, likely due to the absence of revenue details and future guidance. Investors may be cautious as they await more comprehensive financial information in future reports.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MEDPACE HLDGS INC
Feb 14, 2022